| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 526 | 318 | 46 |
| Full Text Views | 4 | 2 | 0 |
| PDF Downloads | 3 | 3 | 0 |
Resistance to Cycloguanil Pamoate (CI-501) by Falciparum Malaria in West Pakistan
Peter G. Contacos
Peter G. Contacos
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
G. Robert Coatney
G. Robert Coatney
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Joseph S. Lunn
Joseph S. Lunn
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Search for other papers by Joseph S. Lunn in
Current site
Google Scholar
PubMed
Search for other papers by Joseph S. Lunn in
Current site
Google Scholar
PubMed
William Chin
William Chin
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Search for other papers by William Chin in
Current site
Google Scholar
PubMed
Search for other papers by William Chin in
Current site
Google Scholar
PubMed
Summary
The repository preparation of cycloguanil pamoate (Camolar®, CI-501) was tested therapeutically against malaria in West Pakistan. Three of the 40 villagers who were treated had recrudescences of their falciparum infections.
The parasite from one of these individuals was established in prisoner volunteers and tested for its susceptibility to various antimalarials. The results of these studies indicated that this strain of falciparum malaria was resistant to chlorguanide and pyrimethamine but susceptible to mepacrine, chloroquine, and quinine.
Author Notes
Laboratory of Parasite Chemotherapy, NIAID, NIH, Malaria Project, U. S. Penitentiary, Atlanta, Georgia.
Chief, Laboratory of Parasite Chemotherapy, NIAID, NIH, Bethesda, Maryland.
Present address: Department of Medicine, University Hospital, Syracuse, New York.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 526 | 318 | 46 |
| Full Text Views | 4 | 2 | 0 |
| PDF Downloads | 3 | 3 | 0 |